Know Cancer

or
forgot password

Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide


Phase 1/Phase 2
18 Years
65 Years
Not Enrolling
Both
Glioblastoma, Glioma

Thank you

Trial Information

Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide


Inclusion Criteria:



- Histologically confirmed glioblastoma multiforme

- Ages 18-65

- Karnofsky Performance Scale (KPS) equal to or less than 70

- Minimal neurological deficit

- Eligible for concurrent temozolomide chemotherapy

Exclusion Criteria:

- Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

determine tumor response and pattern of failure using functional MRI imaging

Outcome Time Frame:

Study completion

Principal Investigator

Bassam Abdulkarim, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Health Services

Authority:

Canada: Health Canada

Study ID:

CNS-09-0027 / ethics 21780

NCT ID:

NCT00250211

Start Date:

March 2005

Completion Date:

April 2011

Related Keywords:

  • Glioblastoma
  • Glioma
  • magnetic resonance imaging, functional
  • radiation therapy
  • temozolomide
  • functional imaging
  • concurrent chemoradiation
  • Glioblastoma
  • Glioma

Name

Location